Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 301 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Neuropathy Assessment Clear all
Recruiting Phase 2 Interventional

Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain

NCT06848348
View directory record Official record
Conditions
Chemotherapy Induced Neuropathic Pain, Chemotherapy Induced Pain Neuropathy, Chemotherapy Induced Pain
Interventions
Halneuron, Placebo, Halneuron (Open Label Extension)
Drug
Lead sponsor
Dogwood Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
25
States / cities
Sheffield, Alabama • Glendale, Arizona • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 3, 2026, 5:34 AM EDT
Active, not recruiting Not applicable Interventional

Pain and Neurological Function Improvements With 10 kHz Spinal Cord Stimulation Treatment of Painful Diabetic Neuropathy

NCT05777317
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
10 kHz SCS, CMM alone
Device · Other
Lead sponsor
Nevro Corp
Industry
Eligibility
22 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Medford, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 3, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)

NCT00633880
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy, Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
Interventions
Placebo, Droxidopa
Drug
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
44
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 3, 2026, 5:34 AM EDT
Completed Not applicable Interventional Results available

Acupuncture in Reducing Chemotherapy-Induced Peripheral Neuropathy in Participants With Stage I-III Breast Cancer

NCT03505671
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Grade 1 Peripheral Motor Neuropathy, CTCAE, Grade 1 Peripheral Sensory Neuropathy, CTCAE, Grade 2 Peripheral Motor Neuropathy, CTCAE, Grade 2 Peripheral Sensory Neuropathy, CTCAE, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
Acupuncture Therapy, Best Practice, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Sep 3, 2026, 5:34 AM EDT
Terminated Phase 2 Interventional Results available

Study of Sulfasalazine in Treating Painful Neuropathy

NCT01667029
View directory record Official record
Conditions
Painful Neuropathy
Interventions
Sulfasalazine, placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Sep 3, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel

NCT02297412
View directory record Official record
Conditions
Acute Pain, Breast Carcinoma, Peripheral Neuropathy
Interventions
Minocycline Hydrochloride, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
12
States / cities
Pismo Beach, California • Normal, Illinois • Urbana, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2022 · Synced Sep 3, 2026, 5:34 AM EDT
Completed Not applicable Interventional

Yoga for Symptoms of Nerve Damage Caused by Chemotherapy

NCT03292328
View directory record Official record
Conditions
Breast Cancer, Peripheral Neuropathy, Gynecologic Cancer
Interventions
Yoga, Wait List Control
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Harrison, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Sep 3, 2026, 5:34 AM EDT
Recruiting Not applicable Interventional

A Virtually Delivered Diet Intervention (LASO-3) for the Improvement of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors Post-treatment

NCT07365007
View directory record Official record
Conditions
Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Educational Intervention, Electronic Health Record Review, Interview, Survey Administration
Procedure · Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 3, 2026, 5:34 AM EDT
Terminated Phase 3 Interventional

Role of Xaliproden on Recovery Rate From Severe Neuropathy in Patients Who Have Completed Adjuvant Chemotherapy With Oxaliplatin Based Regimens

NCT00603577
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Placebo, Xaliproden
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Sep 3, 2026, 5:34 AM EDT
Recruiting Not applicable Interventional

Dehydrated Human Amnion Membrane and Standard of Care Versus Standard of Care Alone in Nonhealing Diabetic Foot Ulcers

NCT06550596
View directory record Official record
Conditions
Diabetic Foot, Ulcer Foot, Foot Ulcer, Diabetic Foot Ulcer
Interventions
Standard of Care, Axolotl DualGraft + SOC
Other
Lead sponsor
Axolotl Biologix
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Thousand Oaks, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Sep 3, 2026, 5:34 AM EDT
Active, not recruiting Phase 2 Interventional

A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy

NCT05405361
View directory record Official record
Conditions
Multifocal Motor Neuropathy (MMN)
Interventions
ARGX-117, Placebo
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
6
States / cities
Scottsdale, Arizona • Glenview, Illinois • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 3, 2026, 5:34 AM EDT
Completed Phase 2Phase 3 Interventional

A Trial to Assess the Efficacy and Safety of SPM 927 in Subjects With Painful Distal Diabetic Neuropathy

NCT00235469
View directory record Official record
Conditions
Diabetic Neuropathy
Interventions
SPM 927
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
496 participants
Timeline
2004 – 2005
U.S. locations
1
States / cities
RTP, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 21, 2014 · Synced Sep 3, 2026, 5:34 AM EDT
Completed Not applicable Interventional

Exercise to Reduce Chemotherapy-Induced Peripheral Neuropathy

NCT03515356
View directory record Official record
Conditions
Gastrointestinal Cancer, Colorectal Cancer, Pancreatic Cancer, Gastric Cancer, Stomach Cancer, Esophageal Cancer
Interventions
MI-Walk Intervention, Physical Activity Education Pamphlet
Behavioral
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Ann Arbor, Michigan • Brighton, Michigan • Canton, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2020 · Synced Sep 3, 2026, 5:34 AM EDT
Enrolling by invitation Not applicable Interventional

Assessment of Carpal Tunnel Syndrome by Shearwave Elastography

NCT04804293
View directory record Official record
Conditions
Carpal Tunnel Syndrome
Interventions
FDA approved ultrasound system with shear wave elastography capability
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 3, 2026, 5:34 AM EDT
Completed Not applicable Interventional

Whole Body Vibration for the Improvement of Health and Functioning in Participants With Chemotherapy-Induced Peripheral Neuropathy

NCT04170075
View directory record Official record
Conditions
Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Whole Body Vibration
Behavioral
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Sep 3, 2026, 5:34 AM EDT
Completed Not applicable Interventional

Impact of an Orthotic Intervention in Children With Peripheral Neuropathy

NCT03655587
View directory record Official record
Conditions
Gait, Drop Foot, Chemotherapy-induced Peripheral Neuropathy, Acute Lymphocytic Leukemia, Pediatric, Rhabdomyosarcoma, Wilms Tumor
Interventions
Solid ankle foot orthotic, Resting night splint
Device
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
5 Years to 14 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Minneapolis, Minnesota • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Sep 3, 2026, 5:34 AM EDT
Recruiting Phase 3 Interventional

Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy

NCT05642611
View directory record Official record
Conditions
Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Cryocompression Therapy, Pneumatic Compression Therapy, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
777 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
36
States / cities
Birmingham, Alabama • Martinez, California • Fairfield, Connecticut + 32 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 3, 2026, 5:34 AM EDT
Completed Not applicable Interventional

Acupuncture/Moxibustion (Acu/Moxa) for Distal Symmetric Peripheral Neuropathy (DSP) in HIV

NCT00826345
View directory record Official record
Conditions
Peripheral Neuropathy, HIV, AIDS, HIV Infections
Interventions
Acupuncture/Moxibustion
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2012 · Synced Sep 3, 2026, 5:34 AM EDT
Active, not recruiting No phase listed Observational

Observational Study to Evaluate the Efficacy of Sustained QUTENZA® Use in Painful Diabetic Peripheral Neuropathy

NCT06495424
View directory record Official record
Conditions
Peripheral Diabetic Neuropathy, Painful Diabetic Neuropathy
Interventions
Capsaicin 8%
Drug
Lead sponsor
Averitas Pharma, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Wilmington, Delaware • Gainesville, Georgia • Jasper, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 3, 2026, 5:34 AM EDT
Terminated Phase 1 Interventional

Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children

NCT02484261
View directory record Official record
Conditions
Leukemia
Interventions
Bortezomib, Pravastatin
Drug
Lead sponsor
Reuven Schore
Other
Eligibility
22 Months to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Sep 3, 2026, 5:34 AM EDT
Completed Phase 1Phase 2 Interventional Results available

L-Serine Supplementation in Hereditary Sensory Neuropathy Type 1

NCT01733407
View directory record Official record
Conditions
Hereditary Sensory and Autonomic Neuropathy Type I
Interventions
L-serine, placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Sep 3, 2026, 5:34 AM EDT
Completed Phase 2 Interventional

Tolerability of Three Local Anesthetic Formulations in Conjunction With NGX-4010 for the Treatment of Neuropathic Pain

NCT00082316
View directory record Official record
Conditions
Herpes Zoster, Neuralgia, Pain, HIV Infections, Peripheral Nervous System Diseases, Diabetic Neuropathies, Diabetes Mellitus, Polyneuropathies
Interventions
Capsaicin Dermal Patch
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
17
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2008 · Synced Sep 3, 2026, 5:34 AM EDT
Completed No phase listed Observational

Optimizing Fall-risk Prediction in Older Adults With Cancer

NCT02912273
View directory record Official record
Conditions
Cancer
Interventions
Baseline Participant Assessment, Baseline Healthcare Provider Assessment, Follow-up Participant Assessment, Follow-up Healthcare Provider Assessment, End-of-study Participant Assessment, End-of-study Healthcare Provider Assessment
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
65 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced Sep 3, 2026, 5:34 AM EDT
Completed Phase 4 Interventional Results available

A Randomized Double-Blind Study Testing the Effects of Pregabalin on Diabetic Neuropathy

NCT00573261
View directory record Official record
Conditions
Diabetic Neuropathy
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 20, 2014 · Synced Sep 3, 2026, 5:34 AM EDT